Baird analyst Michael Ha lowered the firm’s price target on Universal Health (UHS) to $203 from $243 and keeps a Neutral rating on the shares. The firm adjusted the price target after updating its power rankings in managed care and healthcare facilities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Universal Health Services Faces Revenue Uncertainty Amid Medicaid Dependence and State-Level Risks
- Universal Health’s Strong Financial Performance and Future Growth Potential Justify Buy Rating
- Cantor maintains Neutral rating on Universal Health
- Universal Health price target raised to $259 from $257 at Barclays
- Universal Health Services Reports Strong Q2 2025 Results